The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2006Evaluation of the Neuroprotective Peptide NAPVSIPQ in Models of Parkinson's Disease
Parkinson's disease is characterized by the selective loss of dopamine neurons, which leads to reduced control of voluntary locomotor activities. The cause of this degeneration is unknown; however...
-
Therapeutics Development Initiative, 2006Development of Disease Modifying Therapeutic for Parkinson's Disease
Parkinson's Disease is a devastating neurological disorder for which there is no known cure. Our goal is to develop drug candidates to slow or halt the progression of PD. This will be done by focusing...
-
Therapeutics Development Initiative, 2006Neuroprotective Effects of A2A Antagonists in Rodent Models of Motor Function and Dyskinesia
The principal feature of Parkinson's disease is a progressive death of dopamine neurons in the substantia nigra. Pharmacological therapies that enhance dopamine activity effectively treat the rigidity...
-
Therapeutics Development Initiative, 2006Dopaminergic Neurons Derived from Human Embryonic Stem Cells for Transplantation Therapy in Parkinson's Disease
One of the promising potential treatments for halting the progress of Parkinson's disease and restoring lost function is cell replacement using dopamine producing neurons derived from human embryonic...
-
Therapeutics Development Initiative, 2006Preclinical Evaluation of a 5-HT2A Antagonist for Treatment of L-DOPA-Induced Dyskinesias in Parkinson's Disease
The primary motor deficits of Parkinson's disease are effectively improved by administration of the dopamine precursor L-dihydroxyphenylalanine, or levodopa. For unknown reasons, levodopa loses...
-
Therapeutics Development Initiative, 2006Treatment of Parkinson’s Disease with AT2101, a compound that increases the activity of endogenous Glucocerebrosidase
Genetic association studies have suggested a link between Parkinson's and Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the gene GBA, which results in a loss...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.